Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

160 results about "Neurotoxicity" patented technology

Neurotoxicity is a form of toxicity in which a biological, chemical, or physical agent produces an adverse effect on the structure or function of the central and/or peripheral nervous system. It occurs when exposure to substance – specifically, a neurotoxin – alters the normal activity of the nervous system in such a way as to cause permanent or reversible damage to nervous tissue. This can eventually disrupt or even kill neurons, which are cells that transmit and process signals in the brain and other parts of the nervous system. Neurotoxicity can result from organ transplants, radiation treatment, certain drug therapies (e.g., substances used in chemotherapy), recreational drug use, and exposure to heavy metals, bites from certain species of venomous snakes, pesticides, certain industrial cleaning solvents, and certain naturally occurring substances. Symptoms may appear immediately after exposure or be delayed. They may include limb weakness or numbness, loss of memory, vision, and/or intellect, uncontrollable obsessive and/or compulsive behaviors, delusions, headache, cognitive and behavioral problems and sexual dysfunction. Note there is strong evidence that chronic mold exposure in homes can lead to neurotoxicity which may not appear for months to years of exposure. All symptoms listed above are consistent with mold mycotoxin accumulation.

Recombinant live virus vector rabies vaccine without neurotoxicity

The invention discloses a neurotoxicity-free recombinant live virus vector rabies vaccine, which is prepared by replacing G protein of vesicular stomatitis virus with G protein of HEP-Flury rabies virus strain or G protein mutant of HEP-Flury rabies virus strain, and saving recombinant virus VSV-HEP-Flury by using a reverse genetic manipulation technology. The recombinant live virus vector rabies vaccine has no neurotoxicity after being inoculated. The method is free of neurotoxicity, high in safety, simple in inoculation procedure, good in immune effect and high in productivity.
Owner:HEFEI BAIYU BIOTECHNOLOGY CO LTD +1

Application of CD73 + NK cell in preparation of medicine for preventing or treating Parkinson's disease

The invention discloses an application of a CD73 + NK cell in preparation of a medicine for preventing or treating Parkinson's disease. The applicant discovers that the CD73 + NK cell can prevent dopaminergic neuron loss and glial inflammation response of the MPP + induced VM cell in the experimental process. However, TGF-beta1 and IL-10 secreted by the CD73 + NK cells do not significantly prevent loss of dopaminergic neurons induced by MPP + in cross-pore co-culture of the CD73 + NK cells and VM neurons. Therefore, the CD73 + NK cells are proved to protect dopaminergic neurons from the influence of MPP + neurotoxicity through an intercellular contact mechanism, namely CD73-SIRPA interaction.
Owner:SHENZHEN ZHONGJIA BIOMEDICAL TECH CO LTD

Application of compound for inhibiting phosphorylation of ARMC10 in preparation of medicine for antagonizing tin-induced nervous system injury

ActiveCN121606581AOrganic active ingredientsNervous disorderNervous systemMitochondrial Dynamic
The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.
Owner:ARMY MEDICAL UNIV

Phenolic diastereoisomer as well as preparation method and application thereof

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a phenolic diastereoisomer and a preparation method and application thereof.The phenolic diastereoisomer has the chemical structural formula shown in the formula I and the formula II, the formula I is dextroisomer and is named as (+)-fresh bamboo juice phenol D, and the formula II is levoisomer and is named as (-)-fresh bamboo juice phenol D. A pair of phenolic diastereoisomer compounds (+)-fresh bamboo juice phenol D and (-)-fresh bamboo juice phenol D are successfully obtained from fresh bamboo juice, and an anti-neurotoxicity activity test shows that (+)-fresh bamboo juice phenol D has a remarkable protection effect on PC12 cell injury caused by glutamic acid and can be used for preparing medicines for preventing or treating neurodegenerative diseases; wide application prospects are realized.
Owner:JIANGXI INST OF DRUG INSPECTION & TESTING

Lidocaine multivesicular liposome as well as preparation method and application thereof

PendingCN120346166AOrganic active ingredientsAntipyreticAnalgesics drugsAnalgesia postoperative
The invention relates to lidocaine multivesicular liposome as well as a preparation method and application thereof, belongs to the field of medicines, and solves at least one of the problems of higher toxicity, insufficient safety, short action time, limited clinical application range, higher cost and the like of the existing postoperative analgesic medicine. The lidocaine multi-vesicular liposome is prepared from lidocaine and a lipid, wherein the lidocaine and the lipid are added into the lidocaine multi-vesicular liposome; the lipid comprises amphiphilic lipid, negatively charged phospholipid, neutral lipid and cholesterol. The lidocaine multi-vesicular liposome prepared by the preparation method is high in safety, solves the problems of systemic toxicity, neurotoxicity, cardiotoxicity and the like of the existing postoperative analgesic drugs, has the characteristics of long-acting slow release, remarkable analgesic effect and wide clinical application range, and is suitable for clinical application. And a new solution is provided for effectively relieving postoperative pain.
Owner:PEKING UNIVERSITY THIRD HOSPITAL (THE THIRD CLINICAL MEDICAL SCHOOL OF PEKING UNIVERSITY)

Application of traditional Chinese medicine composition in preparation of medicine for relieving side effects of oxaliplatin chemotherapy

The invention discloses application of a traditional Chinese medicine composition in preparation of a medicine for relieving side effects of oxaliplatin chemotherapy. The traditional Chinese medicine composition composed of radix paeoniae alba and liquorice is used for relieving various side reactions caused by oxaliplatin, wherein the side reactions comprise peripheral neurotoxicity, hematological toxicity and systemic reaction. The traditional Chinese medicine composition plays a role in relieving peripheral neurotoxicity caused by oxaliplatin through multiple ways, on one hand, neuroinflammatory response in dorsal root ganglions is inhibited, the dorsal root ganglions are responsible for receiving and conducting sensory nerve impulse, the injury is mainly represented as sensory disorders such as numbness of hands and feet, stabbing pain and delayed feeling, and on the other hand, the neuroinflammatory response in the dorsal root ganglions is inhibited; therefore, OIPN can be relieved by inhibiting the inflammatory reaction; on the other hand, the blood flow of microvessels is promoted, and the circulation disorder of the microvessels at the tail ends of the limbs is improved to relieve OIPN. Moreover, the traditional Chinese medicine composition does not influence the anti-tumor effect of oxaliplatin, is good in safety, and does not damage important organs such as heart, liver, spleen, lung and kidney.
Owner:AFFILIATED HOSPITAL OF JIANGNAN UNIV

Application of serratia marcescens in preparation of medicine for treating gradual freezing

The invention discloses an application of serratia marcescens in preparation of a medicine for preventing or treating gradual freezing (amyotrophic lateral sclerosis, ALS) or frontotemporal dementia (FTD). Specifically, the serratia marcescens of the present invention can improve the phenotype of an asymptomatic and frontotemporal dementia model S59L by reducing mitochondrial unfolded protein response (UPRmt); meanwhile, expression of excitatory amino acid glutamic acid can be reduced, excitatory neurotoxicity can be relieved, and ALS and FTD phenotypes can be relieved through cooperation of the two.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES

Pharmaceutical composition for treating Alzheimer's disease and preparation and detection methods thereof

The invention provides a pharmaceutical composition for treating Alzheimer's disease. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 10-15 parts of ginseng, 10-15 parts of rhizoma acori graminei, 10-15 parts of polygala tenuifolia, 15-20 parts of rhizoma polygonati, 15-20 parts of ginkgo leaves and 5-10 parts of schisandra chinensis. Therefore, the ginseng and the ginkgo leaves jointly regulate a cholinergic system and cerebral blood flow, and the cognitive function is enhanced; the rhizoma acori graminei and the ginkgo leaves cooperate to inhibit aggregation of beta-amyloid protein, improve cerebral circulation and relieve neurotoxicity. Polygonatum sibiricum and Chinese magnoliavine fruit protect nerve cells through anti-oxidation and anti-inflammatory effects and reduce nerve injury. Schizandrin further stabilizes a neurotransmitter system and enhances the synergistic effect of other medicinal materials, a multi-layer treatment network of Abeta deposition inhibition, cholinergic system regulation, anti-inflammation and anti-oxidation and nerve protection is integrally formed, and the core pathological link of the Alzheimer's disease is comprehensively intervened, so that the cognitive function is improved, and the disease progress is delayed.
Owner:SHAANXI XIZHOU PHARM CO LTD

Method for predicting peripheral neurotoxicity induced by treatment of colorectal cancer through oxaliplatin

The invention discloses a method for predicting peripheral neurotoxicity induced by treatment of colorectal cancer through oxaliplatin, and relates to the technical field of drug application, and the method comprises the following steps: obtaining pre-drug patient information before treatment of a patient with oxaliplatin and clinical feature data after use; processing and feature analysis are carried out based on pre-drug patient information and clinical feature data, and a core feature data set related to neurotoxin is determined; and based on the core feature data set, predicting the oxaliplatin-induced peripheral neurotoxicity of the patient by adopting a pre-trained gradient boosting decision tree model, and outputting a prediction risk result. According to the method, the occurrence risk of peripheral neurotoxicity can be accurately predicted according to clinical indexes so as to guide clinical accurate medication.
Owner:AFFILIATED HOSPITAL OF JIANGNAN UNIV

Toxicity-enhanced neurotoxin recombinant protein and application thereof

The application provides a toxicity-enhanced neurotoxin recombinant protein and application thereof, and belongs to the technical field of biological medicine. The recombinant protein comprises a botulinum toxin type A receptor binding domain and at least one GM1 binding peptide inserted into the botulinum toxin type A receptor binding domain, and the recombinin protein can recognize and bind to ganglioside GM1. The short peptide sequence capable of binding to ganglioside GM1 is introduced into the botulinum toxin type A receptor binding domain to obtain the recombinant protein, the binding capacity of the recombinant protein to ganglioside GM1 is enhanced, the target recognition and binding capacity of the recombinant protein to the nerve cell membrane are improved, the overall affinity and endocytosis efficiency of the recombinant protein to the nerve cell are improved, and the neurotoxicity of the botulinum toxin is enhanced. The application not only improves the binding efficiency of BoNT / A in the in-vitro nerve cell model, but also shows a higher toxicity level in the functional verification, and shows a good clinical conversion prospect.
Owner:NORTHWEST A & F UNIV

Intracranial drug balloon catheter and preparation method thereof

The invention belongs to the technical field of medical instruments, and particularly relates to an intracranial drug balloon catheter and a preparation method thereof. A two-time spraying method is adopted, the humidity of carrier gas during two-time spraying is controlled, an amorphous-state drug coating and a crystalline-state combined drug coating are formed on the surface of the balloon catheter, and the drug can be released, permeated and stored within 90 s after the balloon catheter adheres to the wall; further, the technical effects of effectively and lastingly inhibiting the intimal hyperplasia and reducing the restenosis rate are achieved, and the method has excellent trafficability and traceability and can adapt to the complex environment condition of intracranial tortuous blood vessels; meanwhile, the drug coating firmness and release performance can be achieved at the same time, and neurotoxic complications caused by drug falling during in vitro, delivery and expansion are avoided.
Owner:ZHEJIANG BELONGS TO A MEDICAL INSTR

Dihydrotriticale flavones, methods for their preparation and uses thereof

The present application relates to the technical field of medicine, and in particular to a dihydrotricin, a preparation method and use thereof, the preparation method comprising the following steps: taking compound A, diisopropylethylamine and bromomethyl methyl ether to prepare compound B; taking compound C, diisopropylethylamine and bromomethyl methyl ether to prepare compound D; taking compound B and compound D, adding sodium hydroxide to prepare compound E; taking compound E, adding hydrochloric acid to prepare dihydrotricin after washing, separation, and concentration. The preparation method realizes efficient and large-scale synthesis of dihydrotricin. It is first confirmed that dihydrotricin can significantly resist A 1‑42 Oligomer-induced neurotoxicity has broad prospects in preventing and treating middle and late AD and delaying the progression of AD.
Owner:SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)

Application of dehydrounionine in the preparation of drugs that reduce polymyxin toxicity

This invention provides the application of dehydrouncitonin in the preparation of drugs that reduce polymyxin toxicity, belonging to the field of pharmaceutical technology. This invention uses dehydrouncitonin in combination with polymyxin. The combined use of dehydrouncitonin and polymyxin E increased the viability of HEK293T and RAW264.7 cells to 87.7% and 94.3%, respectively, with highly significant differences compared to the control, indicating that treatment with dehydrouncitonin in combination with polymyxin E can significantly inhibit the cytotoxic effect of polymyxin E. This invention uses a mouse model to demonstrate that treatment with dehydrouncitonin in combination with polymyxin E can significantly reduce the neurotoxicity and nephrotoxicity of polymyxin E alone in mice, specifically manifested in improved neurobehavioral effects and improved histopathological effects on brain and kidney tissues. This invention uses dehydrouncitonin in combination with polymyxin E to significantly inhibit the cytotoxic, neurotoxic, and nephrotoxic effects of polymyxin E.
Owner:CHINA AGRI UNIV

Pharmaceutical composition for treating pulmonary fibrosis complicated with depression and application thereof

The invention discloses a pharmaceutical composition for treating pulmonary fibrosis complicated with depression and application of the pharmaceutical composition, and belongs to the field of biological medicine. The pharmaceutical composition provided by the invention comprises harmine and deoxyvasicine, wherein the optimal mass ratio of harmine to deoxyvasicine is 1: 1.25. The curative effect of the pharmaceutical composition is verified by constructing a pulmonary fibrosis and depression combined mouse model, and experimental results show that the pharmaceutical composition provided by the invention can significantly improve the anti-fibrosis effect, can also effectively reduce the neurotoxicity of harmine, shows a synergistic effect, and can be used for preparing anti-fibrosis drugs for treating or preventing the fibrosis. And the curative effect and the safety are both improved. The invention lays a foundation for developing a safe and efficient novel medicine for treating pulmonary fibrosis combined with depression, and has important application value and wide application prospect in treatment of patients with pulmonary fibrosis combined with depression.
Owner:FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY

Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion

The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and / or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and / or neurotoxicity.
Owner:RICHARDSON PAUL G

Nasal injection type baicalein hydrogel as well as preparation method and application thereof

The invention discloses nasal injection type baicalein hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving carboxymethyl chitosan in water, stirring to form a uniform carboxymethyl chitosan solution, then adding a 4-formylphenylboronic acid / baicalein solution, and then continuously stirring until yellow transparent hydrogel is formed, namely the nasal injection type baicalein hydrogel is obtained. The hydrogel has self-healing ability and proper viscosity, can be adhered to the epithelium of the nasal cavity and is continuously released in the microenvironment of the nasal cavity, so that the brain entering efficiency of the baicalein is remarkably improved; neurotoxic oligomers formed by abnormal aggregation of alpha-syn can be reduced; neuroinflammation can be relieved by regulating and controlling phenotypic polarization of microglial cells M2; oxidative stress can be improved by removing excessive ROS, dopaminergic neuron apoptosis is reduced, and the compound can be used for treating Parkinson's disease and has a good application prospect.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

Compositions for treating neurodegenerative diseases and methods thereof

Disclosed herein are compounds and methods of use thereof effective for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells in the brain and spinal cord, eventually causing loss of muscle strength. The compounds of the disclosure include, cutamesine, a synthetic sigma receptor agonist selective for the 81 receptor, and also a chaperone protein of the central nervous system that plays a key role in the modulation of calcium ions and apoptosis, as well as a sapogenin, such as smilagenin, a non-peptide neurotrophic factor that aids in the reversal of free radical neurotoxicity.
Owner:RAYA THERAPEUTIC INC

Method for screening key neurotoxic substances in food raw materials and their products by combining caenorhabditis elegans model with metabolomics

PendingCN122345603ABiotechnologyFood material
This invention discloses a method for screening key neurotoxic substances in food raw materials and their products using a *C. elegans* model combined with metabolomics. Food samples are processed to prepare a stock solution, which is then used to cultivate *C. elegans*. The sample exhibiting the greatest neurotoxicity to the nematodes is identified by analyzing the number of *C. elegans* movements and neuronal fluorescence images. Subsequently, key neurotoxic substances in food are systematically screened using a combination of non-targeted liquid chromatography-tandem mass spectrometry (LC-MS / MS) and a metabolomics platform. This application establishes a novel method for screening neurotoxic substances by combining nematode activity with non-targeted LC-MS / MS determination and a non-targeted metabolic platform, clarifying key neurotoxic substances in food and providing a theoretical basis for food quality control and high-quality development.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Pharmaceutical composition for preventing or treating degenerative brain diseases, comprising prasugrel as active ingredient

PCT designated stageWO2025159459A1Organic active ingredientsNervous disorderMicroglial cell activationBULK ACTIVE INGREDIENT
The present invention relates to a pharmaceutical composition for preventing or treating degenerative brain diseases, the composition comprising prasugrel as an active ingredient. The composition containing prasugrel or a salt thereof according to the present invention has excellent neuroprotective activity and, in particular, can suppress MPP+-induced neurotoxicity and neuronal cell death, suppress LPS-induced microglial cell activation and cell migration, and has neuroinflammation inhibitory activity, and thus has the effect of preventing, alleviating, and treating various degenerative brain diseases including Parkinson's disease.
Owner:DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

A photosensitizer targeting beta amyloid and its preparation method and application

The application discloses a photosensitizer targeting beta amyloid, and a preparation method and application thereof. The photosensitizer is a photosensitizer with A-D-A configuration, and a structural formula thereof is shown as formula I. The photosensitizer synthesized in the application has a longer emission wavelength, and after being combined with beta amyloid, the fluorescence signal is obviously enhanced, and can effectively generate singlet oxygen, that is, the photosensitizer can target mark A beta protein, and is used for fluorescence imaging of the A beta protein; and after the photosensitizer synthesized in the application is combined with beta amyloid in the brain of an Alzheimer's disease (AD) model mouse, the cognitive ability of the AD mouse can be effectively improved, A beta-mediated neurotoxicity can be reduced, and clearance of A beta plaques can be promoted, that is, the photosensitizer can be used for early diagnosis and treatment of Alzheimer's disease.
Owner:SOUTH CHINA UNIV OF TECH

Method for predicting accurate dosage of polymyxin B for multi-drug-resistant severe infection patient

The invention relates to the technical field of drug information, in particular to a method for predicting the accurate dosage of polymyxin B for a multi-drug-resistant severe infection patient, which comprises the following steps: acquiring model establishment data, establishing a basic model, incorporating covariables, evaluating the model, performing external verification and simulating based on the model. According to the method provided by the invention, accurate prediction of medication of the polymyxin B is realized, and death of a patient with severe infection caused by anti-infection failure due to too low dosage of the polymyxin B is reduced; the situation that the health of a severe patient is seriously damaged due to serious renal toxicity and neurotoxicity side effects caused by overlarge dosage of the polymyxin B is avoided, and the method has important significance on precise medication of clinically refractory severe infection patients.
Owner:江西省肿瘤医院(江西省第二人民医院 江西省癌症中心)

Application of miRNA in preparation of medicine for preventing and treating Parkinson's disease

The invention discloses an application of miRNA (micro Ribonucleic Acid) in preparation of a medicine for preventing and treating Parkinson's disease, and particularly provides an application of miRNA, which is miR-363-3p, miR-146b-3p, miR-24-2-5p, miR-26a-5p and miR-22-3p and plays a role in neuroprotection in SKP-SC-EVs (SKP-SC-EVs). Wherein the miR-146b-3p has the best effect of improving the activity of damaged nerve cells, and can recover TCA cycle key enzyme down-regulation caused by neurotoxic substances, and inhibition of the miR-146b-3p can lead to cell activity weakening with increased SKP-SC-EVs. The invention provides miRNA for protecting dopaminergic neurons by adjusting mitochondrial functions and energy metabolism, can be applied to preparation of drugs for preventing and treating Parkinson's disease, and is beneficial to prevention and treatment of Parkinson's disease and other neurodegenerative diseases.
Owner:NANTONG UNIV

Use of fractalkine in the preparation of a medicament for preventing or treating repair of white matter damage

This invention provides the application of fractalkine in the preparation of drugs for the prevention or treatment of white matter injury repair. In animal models of cerebral hemorrhage, it was found that the mass effect of hematoma in the basal ganglia and the neurotoxic products generated by its lysis lead to damage to surrounding white matter fiber bundles. Fractalkine plays an important role in regulating microglial activation after cerebral hemorrhage to promote white matter repair.
Owner:THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV

A method and system for assessing car-t treatment-related neurotoxicity based on behavioral characteristics

The application discloses a method and system for evaluating CAR-T treatment related neurotoxicity based on behavior characteristics, relates to the technical field of medical behavior analysis, and provides the following scheme, which comprises the following steps: synchronously collecting angular velocity time series data of double upper limbs of a patient and electromyographic signals corresponding to muscle surfaces of the double upper limbs; performing frequency band optimization filtering on the angular velocity time series data of the double upper limbs respectively; generating angular velocity waveforms; taking a wave peak time point of the angular velocity waveform as a reference; extending forward for a preset time length; and calculating an energy integral curve of the electromyographic signals. The angular velocity time series data of the double upper limbs is processed through frequency band optimization to generate angular velocity waveforms, the energy integral curve of the electromyographic signals is extracted forward based on the wave peak time point of the angular velocity, candidate time points are obtained, and local cross-correlation analysis is enabled to locate and intercept points when the wave peak value is lower than a preset threshold, so that the problem of missing weak tremor signals is solved, effective detection and reliable interception of low-amplitude tremors are realized, and weak signal features are avoided from being lost.
Owner:SUN YAT SEN UNIV

Use of gallic acid in the preparation of a medicament for preventing or treating peripheral neuropathy

The application relates to a pharmaceutical application technology, in particular to application of gallic acid in preparation of a medicine for preventing or treating peripheral neuropathy. The peripheral neuropathy is acute peripheral neuropathy caused by using a chemotherapy drug, oxaliplatin. The gallic acid has a protective effect on acute peripheral nerve toxicity of mice induced by oxaliplatin. The medicine, gallic acid, can be used as an adjuvant of a chemotherapy drug for cancer treatment, and has a significant alleviating effect on nerve toxicity caused by chemotherapy.
Owner:JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE

Umami peptide without nervous excitatory toxicity as well as preparation process and application of umami peptide

The invention provides an umami peptide without nervous excitatory toxicity and a preparation process and application thereof, the umami peptide is extracted from broad bean protein, and the amino acid sequence is shown as SEQ ID NO.1 and / or SEQ ID NO.2. Compared with a traditional umami substance-sodium glutamate (monosodium glutamate MSG), the umami peptide has the characteristics of activating umami receptors TAS1R1 / TAS1R3 without acting on sodium glutamate receptors such as NMDA and the like, and has the advantages that the umami peptide can be used for preparing the umami peptide. No NMDA receptor mediated excitatory neurotoxicity exists; meanwhile, the umami peptide can stimulate intestinal endocrine cells (STC-1) to secrete GLP-1.
Owner:ZHEJIANG UNIV

Application and products of metabolic markers in the preparation of products for monitoring PB neurotoxicity

Disclosed are the use of a metabolic marker in the preparation of a product for monitoring PB neurotoxicity and a product thereof, which can be used for the early diagnosis of PB neurotoxicity with high sensitivity, rapidity, convenience, and accurate and reliable results. The metabolic markers include LysoPE 20:4 / 0:0, creatine, SM d18:1 / 24:0, SM d18:0 / 24:1, LysoPC 18:0, palmitoyl sphingomyelin, phosphocholine, PC 14:0 / 22:1, creatinine, PC 18:3 / 16:0, SM d18:1 / 16:0, sphingosine, choline, LysoPC 18:1, L-carnitine, palmitic acid, PC 18:0 / 20:4, 3-hydroxy-2-octylglutaric acid, L-acetylcarnitine, LysoPC 20:4, LysoPC 16:0, and PC 20:1 / 14:1.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Microorganism-intestine-brain axis-based neurotoxicity antagonist screening and evaluation method

The invention belongs to the field of bioengineering and neurotoxicity prevention and control, and particularly relates to a neurotoxicity antagonist screening and evaluating method based on a microorganism-intestine-brain axis. The screening method of the neurotoxicity antagonist comprises the following steps: establishment of a neurotoxicity animal model, verification of the neurotoxicity model, sequencing of intestinal flora and screening of key flora, coupling analysis of flora-cranial nerve indexes, verification of candidate microorganisms, screening of core bacterial metabolites, verification of the core bacterial metabolites and verification of the core bacterial metabolites. According to the method, through behavior-neurotransmitter-inflammation-gene / mitochondrial function multi-level index linkage, a reproducible recovery index (RI) index is established, and quantitative screening and grading judgment of candidate strains and metabolites of the candidate strains on nerve injury repair are achieved.
Owner:NANJING AGRICULTURAL UNIVERSITY +1

Application of HIF-1alpha inhibitor in preparation of product for inducing transformation of astrocytes from pro-inflammatory type to anti-inflammatory type

The invention belongs to the technical field of biological medicines, and relates to application of an HIF-1alpha inhibitor in preparation of a product for inducing transformation of astrocytes from a pro-inflammatory type to an anti-inflammatory type. The invention reveals that activation of an HIF-1 signal channel is an important mechanism for driving neuroinflammatory response and pro-inflammatory A1 type astrocyte formation, and inhibition of HIF-1 activation can effectively promote generation of neuroprotective A2 type astrocytes. By applying the HIF-1alpha small-molecule inhibitor KC7F2 to astrocytes, HIF-1alpha activation is blocked, and the astrocytes are promoted to be converted from a proinflammatory A1 phenotype to an anti-inflammatory A2 phenotype, so that inflammatory response is inhibited, neurotoxicity is reduced, and a neuron microenvironment is improved. The invention provides a novel intervention strategy based on HIF-1alpha signal regulation and control, and a novel theoretical basis and a novel potential drug treatment scheme are provided for treatment of nervous system injury and related neurodegenerative diseases.
Owner:SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI

Caenorhabditis elegans exposure evaluation method based on neural behavior multi-parameter integration

The invention relates to the technical field of biological detection and toxicological evaluation, and discloses a neural behavior multi-parameter integration-based caenorhabditis elegans exposure evaluation method which comprises the following specific steps: S1, synchronous culture of caenorhabditis elegans; s2, pollutant exposure treatment; s3, multi-parameter behavior detection; s4, data standardization processing; and S5, constructing a comprehensive evaluation model, and performing weighted integration on four core parameters including the movement speed, the chemotactic index, the synaptic spot density and the calcium signal amplitude after standardization to construct a neurotoxicity index NTI. According to the method disclosed by the invention, a multi-layer and multi-dimensional neurotoxicity evaluation system is constructed by integrating four types of neurobehavior parameters including motion behaviors, chemotactic reactions, synaptic morphology and neuron calcium signals, and the defect that a traditional single endpoint index cannot comprehensively reflect overall disturbance of a neural regulation network is overcome; by utilizing the high homology of the nervous system of caenorhabditis elegans and the human nerve gene, the clinical correlation and mechanism analysis capability of environmental pollutant neurotoxicity evaluation are remarkably improved.
Owner:SOUTHEAST UNIV